TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00297206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
Study: NCT03384420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ cells enriched with MNV-BLD
Description: Transplantation of autologous stem cell enriched with MNV-BLD (blood-derived mitochondria)
Study: NCT01491282

Intervention type: OTHER
Intervention: Enabling and disabling VNS
Description: No intervention
Study: NCT01241812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower limb muscle strengthening
Description: Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
Study: NCT04408300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmological exam
Description: Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
Study: NCT00350337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pre-transfection F17
Description: Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post-transfection F17
Description: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post-transfection F19
Description: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
Study: NCT04471558

Intervention type: OTHER
Intervention: Music
Description: A part of the RCT will be performed with music in the room. The music will be switch on just before anesthesia and off after the postoperative rest.
Study: NCT03319381

Intervention type: BEHAVIORAL
Intervention: Following new SOPs
Description: The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs

Intervention type: BEHAVIORAL
Intervention: Following new SOPs
Description: The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs
Study: NCT02464085

Intervention type: OTHER
Intervention: Longitudinal evaluation of recovery
Description: Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
Study: NCT03786809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimifuga Racemosa
Description: Experimental group will use 160mg of Cimifuga Racemosa for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients of the placebo group will use placebo once a day for 28 days
Study: NCT00827073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracaine 0.5%
Description: betadine 5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Jelly
Description: Betadine 5%
Study: NCT00831467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV9103
Description: Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
Study: NCT01862120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose D1 of interleukin-2
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose D2 of Interleukin-2
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose D3 of interleukin-2
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Study: NCT00289731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TWINRIX™
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAVRIX™
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HB VAX PRO™
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaqta™
Description: Intramuscular injection, 2 doses
Study: NCT01718301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Study: NCT04553484

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT01058044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System 
Description: Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy
Study: NCT00443131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Malaria vaccine 257049
Description: Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Malaria vaccine 257049
Description: Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Malaria vaccine 257049
Description: Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
Study: NCT00887107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (nexavar)
Description: 6 months therapy with Sorafenib 800 mg/day
Study: NCT04626765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22 CAR-T
Description: CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD 19+22
Description: CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/㎡ for D-4、D-3 and D-2
Study: NCT02239523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Letter Group
Description: At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
Study: NCT04626765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/㎡ for D-3 and D-2
Study: NCT01339884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
Study: NCT03401970

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acellular carbohydrate diet
Description: Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cellular carbohydrate diet
Description: Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate high-fat diet
Description: Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
Study: NCT03251469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 15mg/kg , iv, Single Dose
Description: Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline, 100mg, iv, Singe dose
Description: Normal Saline, 100mg, administered intravenously, preoperatively in single dose
Study: NCT02585531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline 3%
Description: The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine and Dexamethasone
Description: The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours.
Study: NCT03346668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical gabapentin
Description: topical gabapentin 6% solution
Study: NCT04346758

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar plexus block
Description: Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
Study: NCT03091751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeneFIX
Description: BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
Study: NCT00497380

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Oral nutritional supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Arginine
Description: Oral nutritional supplement
Study: NCT01296568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously
Study: NCT02484794

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Outpatient Treatment
Description: Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Outpatient Treatment
Description: Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
Study: NCT04984044

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Dietary supplement:Vitamin D3~1 capsule of Vitamin D3 (40,000IU) weekly for 8 weeks with antidiabetic drug

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule weekly for 8 weeks with antidiabetic drug
Study: NCT02574975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methacholine
Description: Methacholine,inhaled cumulative dosage 2.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine monophosphate
Description: Adenosine monophosphate ,inhaled cumulative dosage 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leukotriene D4
Description: Leukotriene D4,inhaled cumulative dosage 2.4 μg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astograph Jupiter-21 airway reaction testing apparatus
Description: Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide /formoterol
Description: budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
Study: NCT04423965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day \*2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Capecitabine based chemoradiotherapy
Study: NCT01373086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01123759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feeding low mercury fish
Description: Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feeding low mercury fish
Description: Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
Study: NCT03050476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESCAP®
Description: intravenous application before, during, and for 24 or 96 hours after heart surgery
Study: NCT02567266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Adolescents (UP-A)
Description: The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Outcomes Questionnaire
Description: The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision.
Study: NCT03050476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous application before, during, and for 24 or 96 hours after heart surgery